JHS Svendgaard Laboratories Limited has informed the Exchange about approval of JHS ESOP Scheme 2025 from shareholders in 21 Annual General Meeting of the Company.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JHS Svendgaard Laboratories has received shareholder approval for its new Employee Stock Option Plan, JHS ESOP Scheme 2025, at the 21st Annual General Meeting held on 20 September 2025. The scheme creates a pool of 40 lakh (4 million) stock options, with each option convertible into one equity share of Rs. 10 face value. The options will be granted through fresh allotments (direct route), administered by the Nomination and Remuneration Committee, and priced with reference to the market price at the time of grant, subject to a floor at face value. Vesting will happen over 1 to 5 years from the grant date, and vested options can be exercised within 5 years of each vesting. No options have been granted yet under the scheme.
This is a governance/disclosure event rather than a near-term price catalyst — no options have actually been granted yet, so there is no immediate dilution or cash impact. However, the approved pool of 40 lakh shares represents a potential future dilution that shareholders should monitor, especially as the exercise price and timing of grants are disclosed by the company.